Further in line with this idea, a recent study identified hepatocyte PPARα as a relevant sexually dimorphic target in NAFLD, with potential consequences on therapeutic responses targeting this nuclear receptor [43]. Here, PPARA is linked to metabolic dysfunction-associated steatotic liver disease.